OurCrowd portfolio company ReWalk, developer of the FDA approved ReWalk exoskeleton device, was featured in Financial Times. ReWalk is the developer of the FDA approved ReWalk exoskeleton device, providing paraplegics with an independent, natural walking experience that provides them numerous social, psychological, and physical benefits.

Rewalk is one of a handful of technology companies that make high-tech wearable robotic exoskeletons for wheelchair users, a fledgling market that is slowly beginning to take off. Last year, tetraplegic Irving Caplan, who was paralysed after a cycling accident 18 years ago, made headlines after he crossed a dance floor wearing a pair of Rex Bionic legs to deliver a speech at his daughter’s wedding in St Albans, Hertfordshire.

Mr Johnson says he tried a number of exoskeleton devices but Rewalk’s system suited him best. The 20 kilogrammes device, which costs £40,350, holds the legs in place and uses sensors to know which direction the person wants to walk by the tilt of their body. It is powered by a rechargeable battery in a backpack and a digital watch allows the user to programme what it wants to do, such as walk, sit or climb stairs.


ReWalk raised $1,320,000 from OurCrowd investors in June 2013.

Read more on Financial Times here.